SAB Biotherapeutics reported Q3 2026 results highlighting full enrollment of adult and adolescent cohorts in the SAFEGUARD Phase 2b study for SAB-142, a treatment for Stage 3 type 1 diabetes (T1D). The pediatric cohort is actively enrolling, with full enrollment expected by Q4 2026 and topline data anticipated in the second half of 2027. SAB-142 received FDA Fast Track designation, accelerating its development for new-onset Stage 3 T1D. The company has $205.3 million in cash, supporting operations through 2028, and is progressing a Phase 3 study (PRISE-hATG) for patients diagnosed up to two years prior. SAB BIO aims to complete enrollment, execute regulatory strategy, and deliver data to potentially change T1D treatment.
SAB BIO's Q3 2026 financial results and business highlights provide context for readers interested in health sector trends. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: out of 150 priced US health stocks, 94 rose and 48 fell. Notably, ADMA Biologics Inc (ADMA) surged 19.56% with a typical hold time of 20 days and 100% sell order activity, contrasting with Becton Dickinson and Co (BDX), which dropped 6.86% and has a much longer typical hold time of 105 days with also 100% sell orders. Revolution Medicines Inc (RVMD) gained 7.14% with a shorter hold time of 10 days.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
